Real-World Outcomes of Patients With NSCLC Treated With PD-1 Inhibitors After Approval
Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.
Immunotherapies Often Fail to Show Durable Survival in ASCO Value Framework
Results of a recent analysis showed that only 3 drug indications of 6 immuno-oncology agents met the durable survival threshold in the American Society of Clinical Oncology value framework.
Most Cost-Effective Treatment Regimen Identified for Relapsed, Refractory Multiple Myeloma
A recent cost-effectiveness analysis evaluated treatments for relapsed or refractory multiple myeloma from a United States health system perspective.
RA Biomarker Panel Identifies Older Patients at Risk of Cardiovascular Events
Higher scores on a multibiomarker disease activity system are associated with hospital infection, myocardial infarction, and coronary heart disease events in older patients with rheumatoid arthritis.
Optimal First-Line Treatment for ALK-Positive Advanced NSCLC Identified
A recent study compared a targeted therapy with standard chemotherapy for treatment-naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.
Intravenous Combination Regimen Safe, Effective in Older Patients With Type of Blood Malignancy
A potential new first-line therapeutic option may have been identified for older patients with a common blood cancer type.
How Severe Are Immunotherapy Adverse Events for Cancer and Preexisting Autoimmune Disease?
A recent study summarized the available evidence on adverse events associated with checkpoint inhibitors in patients with cancer and preexisting autoimmune disease.
Optimal Implementation Strategy for Blood Pressure Control Identified in Patients With Hypertension
A comparative effectiveness study analyzed various implementation strategies for BP control in patients with hypertension.
VA Better Than Medicare in End-of-Life Care for Patients With Cancer
Patients with cancer treated through the Department of Veterans Affairs are less likely to receive excessive end-of-life interventions than patients treated through Medicare.
